Briefing
Abstract PD5-03: PD5-03 Comparison of a personalized sequencing assay and digital PCR for circulating tumor DNA based Molecular Residual Disease detection in early-stage triple negative breast cancer in the cTRAK-TN trial
Overall test agreement was 92.7% (95% CI 90.7-94.4%). From a patient-level view, 58.7% were negative on both assays, 32.9% positive on both, and 8.6% discordant (ctDNA detected by RaDaR but not dPCR in 9 patients, and the reverse in 3). Among ctDNA-positive patients, 55.2% were first detected by RaDaR, 5.2% by dPCR, and 39.6% at the same timepoint (P<0.001). Median lead time to relapse was 7.1 months with RaDaR vs 5.7 months with dPCR.
- Design: poster discussion
- n: Agreement and lead-time comparison on c-TRAK TN samples; exact patient n is given in rates (9 patients RaDaR-only positive, 3 dPCR-only) but a single total n is not restated as a standalone figure in the extracted results beyond the agreement analysis
- Assay: RaDaR (personalized multi-mutation sequencing) compared with digital PCR mutation tracking